Logo

Cergentis: Jan Groen, Wim Van Criekinge, Maaike Van Min

Sep 19, 2019

The Netherlands-based genomics company Cergentis has appointed Jan Groen, Wim Van Criekinge, and Maaike Van Min to its board of directors. Groen currently serves as CEO of Novigenix. Van Criekinge has over 20 years of experience in the life sciences industry as a strategic, scientific consultant and business executive in diagnostic and biotech companies. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.